Results 81 to 90 of about 39,039 (378)

Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing [PDF]

, 2017
The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage marker FcRH5 expressed in multiple myeloma (MM) tumor cells. We demonstrate that TDBs trigger T cell receptor activation by inducing target clustering and exclusion ...
Clark, V, Cook, R, Danilenko, D, DiCara, D, Ellerman, D, Harris, MJ, Hristopoulos, M, Hötzel, I, James, JR, Johnston, J, Junttila, TT, Lee, GY, Li, J, Luis, E, McCarty, L, Menzies, SA, Nakamura, R, Slaga, D, Stagg, NJ, Sukumaran, S, Sumiyoshi, T, Totpal, K, Wu, TD, Ye, Z   +23 more
core   +2 more sources

A Novel Class of Multi‐substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155

Advanced Science, EarlyView.
Structural modification of clofoctol yielded a novel blood‐brain barrier‐permeable compound, B7, featuring a multi‐substituted diaryl scaffold. B7 demonstrates potent anti‐glioblastoma activity by suppressing glioblastoma stem cells proliferation, migration, and invasion through interactions with five key residues of poliovirus receptor cell adhesion ...
Yong‐jian Wang, Ting Sun, Si‐tu Xue, Zhong‐di Cai, Hong Yi, Miao Lv, Shi‐bo Kou, Rui Liu, Xiao‐zhong Peng, Zhuo‐rong Li   +9 more
wiley   +1 more source

Potential Neutralizing Antibodies Discovered for Novel Corona Virus Using Machine Learning [PDF]

arXiv, 2020
The fast and untraceable virus mutations take lives of thousands of people before the immune system can produce the inhibitory antibody. Recent outbreak of novel coronavirus infected and killed thousands of people in the world. Rapid methods in finding peptides or antibody sequences that can inhibit the viral epitopes of COVID-19 will save the life of ...
arxiv  

Development of a DNA Aptamer‐Based Approach to Noninvasively Image CAR‐T Cells In Vivo and Traceless Enrichment In Vitro

Advanced Science, EarlyView.
A DNA aptamer (A3) with nanomolar affinity for CAR‐T cells is developed via Cell‐SELEX. In Nalm6 tumor‐bearing mice, Cy5‐labeled A3 enables long‐term fluorescence imaging and tracks the biodistribution of CAR‐T cells, with tumor signal peaking on day 14 after CAR‐T cell administration.
Minghui Chen, Pengzhao Chang, Zhen Zhang, Dan Liu, Rui Hou, Ming Shi, Jingjing Li, Kai Xu, Junnian Zheng   +8 more
wiley   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source

Antibody engineering for increased potency, breadth and half-life [PDF]

, 2015
Purpose of review: This review highlights recent developments in HIV-1 antibody engineering and discusses the effects of increased polyreactivity on serum half-lives of engineered antibodies.
Bjorkman, Pamela J., Scharf, Louise, Sievers, Stuart A., West, Anthony P., Jr.   +3 more
core   +1 more source

Application of humanized mice in the safety experiments of antibody drugs

Animal Models and Experimental Medicine, EarlyView.
The graphical abstract of this review highlights the critical role of humanized mice in the safety evaluation of antibody drugs. First, the inherent immunogenicity of antibody drugs can lead to the production of antidrug antibodies and hypersensitivity reactions on repeated administration.
Zhimin Sun, Mengyun Gu, Zixuan Yang, Lei Shi, Liyuan Zhao, Minhui Zheng, Yan Wang, Wei Zhang, Kexin Han, Naping Tang   +9 more
wiley   +1 more source

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy

Molecular Therapy: Methods & Clinical Development, 2017
Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone ...
Robert L. Kruse, Thomas Shum, Xavier Legras, Mercedes Barzi, Frank P. Pankowicz, Stephen Gottschalk, Karl-Dimiter Bissig   +6 more
doaj   +1 more source

Detection of CD33 expression on monocyte surface is influenced by phagocytosis and temperature [PDF]

, 2019
CD33 is a myeloid-associated marker and belongs to the sialic acid-binding immunoglobulin (Ig)-like lectin (Siglec) family. Such types of receptors are highly expressed in acute myeloid leukemia, which could be used in its treatment.
Baisaeng, Nuttakorn, Boonla, Chanchai, Bäumler, Hans, Georgieva, Radostina, Kaewprayoon, Waraporn, Kloypan, Chiraphat, Smuda, Kathrin, Suwannasom, Nittiya   +7 more
core   +1 more source

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

Journal of Hematology & Oncology, 2021
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies.
Zheng Tian, Ming Liu, Ya Zhang, Xin Wang
doaj   +1 more source